A Case Series on Patients on Tofacitinib in Combination With a Biologic

被引：14
作者：
Barroso, Nashla S. [1 ]
Miller, Elizabeth Z. [1 ]
Furst, Daniel E. [1 ,2 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Rheumatol, Los Angeles, CA 90095 USA
[2] Pacific Arthrit, Los Angeles, CA USA
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷 / 06期
关键词：
RHEUMATOID-ARTHRITIS; PSORIATIC-ARTHRITIS; DOUBLE-BLIND; CLASSIFICATION; INHIBITION; CRITERIA; THERAPY; TRIAL;
D O I：
10.1097/RHU.0000000000000663
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：349 / 351
页数：3
相关论文
共 14 条
  • [1] [Anonymous], 2016, What is a serious adverse event?
  • [2] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS
    ARNETT, FC
    EDWORTHY, SM
    BLOCH, DA
    MCSHANE, DJ
    FRIES, JF
    COOPER, NS
    HEALEY, LA
    KAPLAN, SR
    LIANG, MH
    LUTHRA, HS
    MEDSGER, TA
    MITCHELL, DM
    NEUSTADT, DH
    PINALS, RS
    SCHALLER, JG
    SHARP, JT
    WILDER, RL
    HUNDER, GG
    [J]. ARTHRITIS AND RHEUMATISM, 1988, 31 (03): : 315 - 324
  • [3] Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist
    Charles-Schoeman, Christina
    Gonzalez-Gay, Miguel A.
    Kaplan, Irina
    Boy, Mary
    Geier, Jamie
    Luo, Zhen
    Zuckerman, Andrea
    Riese, Richard
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (01) : 71 - 80
  • [4] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    Cohen, Stanley B.
    Emery, Paul
    Greenwald, Maria W.
    Dougados, Maxime
    Furie, Richard A.
    Genovese, Mark C.
    Keystone, Edward C.
    Loveless, James E.
    Burmester, Gerd-Ruediger
    Cravets, Matthew W.
    Hessey, Eva W.
    Shaw, Timothy
    Totoritis, Mark C.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : 2793 - 2806
  • [5] Combination Biologic Treatment of Refractory Psoriasis and Psoriatic Arthritis
    Cuchacovich, Raquel
    Garcia-Valladares, Ignacio
    Espinoza, Luis R.
    [J]. JOURNAL OF RHEUMATOLOGY, 2012, 39 (01) : 187 - 193
  • [6] Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
    Downey, Colum
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (06) : 536 - 550
  • [7] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
    Genovese, MC
    Becker, J
    Schiff, M
    Luggen, M
    Sherrer, Y
    Kremer, J
    Birbara, C
    Box, J
    Natarajan, K
    Nuamah, I
    Li, T
    Aranda, R
    Hagerty, DT
    Dougados, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) : 1114 - 1123
  • [8] Effect of Combination Therapy on Joint Destruction in Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials
    Graudal, Niels
    Hubeck-Graudal, Thorbjorn
    Tarp, Simon
    Christensen, Robin
    Jurgens, Gesche
    [J]. PLOS ONE, 2014, 9 (09):
  • [9] Tofacitinib versus Methotrexate in Rheumatoid Arthritis
    Lee, Eun Bong
    Fleischmann, Roy
    Hall, Stephen
    Wilkinson, Bethanie
    Bradley, John D.
    Gruben, David
    Koncz, Tamas
    Krishnaswami, Sriram
    Wallenstein, Gene V.
    Zang, Chuanbo
    Zwillich, Samuel H.
    van Vollenhoven, Ronald F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (25) : 2377 - 2386
  • [10] Rituximab for the treatment of rheumatoid arthritis: an update
    Mok, Chi Chiu
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 87 - 100
12